First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene
- PMID: 23162007
- DOI: 10.1177/0003319712465171
First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene
Abstract
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder. Mutations have been found in at least 3 genes: the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9). We report the first case of FH in an Omani family due to a novel mutation in the LDLR gene. A 9-year-old female was referred to our lipid clinic with eye xanthelasmata and thickening of both Achilles tendons. Evaluation of the lipid profile showed the off treatment total cholesterol of 896 mg/dL (23.2 mmol/L), low-density lipoprotein cholesterol (LDL-C) of 853 mg/dL (22.1 mmol/L), APOB of 4.5 g/L, triglyceride of 71 mg/dL (0.8 mmol/L), and high-density lipoprotein cholesterol of 0.74 mmol/L. Genetic analysis of the LDLR gene showed a homozygous frameshift deletion mutation (272delG) at exon 3. The female patient was treated with a combination of rosuvastatin/ezetimibe and LDL apheresis.
Similar articles
-
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.Eur J Prev Cardiol. 2017 Jul;24(10):1051-1059. doi: 10.1177/2047487317702040. Epub 2017 Mar 29. Eur J Prev Cardiol. 2017. PMID: 28353356
-
Severe xanthomatosis in heterozygous familial hypercholesterolemia.J Clin Lipidol. 2018 Jul-Aug;12(4):872-877. doi: 10.1016/j.jacl.2018.03.087. Epub 2018 Apr 3. J Clin Lipidol. 2018. PMID: 29778561
-
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.Int Angiol. 2010 Dec;29(6):514-24. Int Angiol. 2010. PMID: 21173733 Clinical Trial.
-
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.Atherosclerosis. 2012 Aug;223(2):262-8. doi: 10.1016/j.atherosclerosis.2012.02.019. Epub 2012 Feb 16. Atherosclerosis. 2012. PMID: 22398274 Review.
-
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):414-422. doi: 10.1016/j.pcad.2019.10.003. Epub 2019 Oct 25. Prog Cardiovasc Dis. 2019. PMID: 31669498 Review.
Cited by
-
Lomitapide: navigating cardiovascular challenges with innovative therapies.Mol Biol Rep. 2024 Oct 21;51(1):1082. doi: 10.1007/s11033-024-10003-y. Mol Biol Rep. 2024. PMID: 39432146 Review.
-
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.Oman Med J. 2013 Jan;28(1):48-52. doi: 10.5001/omj.2013.11. Oman Med J. 2013. PMID: 23386946 Free PMC article.
-
Ocular manifestations of severe familial hypercholesterolemia.Heliyon. 2024 Apr 30;10(9):e30487. doi: 10.1016/j.heliyon.2024.e30487. eCollection 2024 May 15. Heliyon. 2024. PMID: 38737271 Free PMC article.
-
Clinical and Genetic Characteristics of Familial Hypercholesterolemia at Sultan Qaboos University Hospital in Oman.Oman Med J. 2020 Jun 30;35(3):e141. doi: 10.5001/omj.2020.59. eCollection 2020 May. Oman Med J. 2020. PMID: 32704389 Free PMC article.
-
Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel.Curr Vasc Pharmacol. 2015;13(6):759-70. doi: 10.2174/1570161113666150827125040. Curr Vasc Pharmacol. 2015. PMID: 26311574 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous